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Abstract
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The low quality of life of patients with schizophrenia has been extensively discussed and
investigated. Various aspects from gender, socio-demographic profile, and/or type of neuroleptic
treatment have been taken into account in describing this condition. The purpose of this study is
to assess the perceived quality of life of Romanian patients suffering from schizophrenia and to
correlate it with gender differences, type of schizophrenia, family history of psychiatric illness,
and type of antipsychotic treatment. 143 patients diagnosed with schizophrenia according to DSM
IV-TR and ICD 10 were included in the study. Social demographic data were documented and
further assessment was performed using the Subjective Well Being under Neuroleptic Treatment
Scale –the short form (SWN-S) and the short version of the WHO- Questionnaire for The Quality
of Life (WHO-QoL-BREF). The mental functioning dimension was higher in men than women;
the social integration dimension was higher for the residual type of schizophrenia. Emotional
regulation and the capacity of social integration did not show significant differences between
patients who had a family history of mental illness and those who did not. Levels of self-control
and physical functioning were better for patients treated with atypical antipsychotics and who did
not report a family history of psychiatric illness. All five dimensions of the SWN-S were higher
in patients treated with atypical antipsychotics, compared to those who were treated with typical
antipsychotics. The study showed that for people with schizophrenia mental functioning was
better preserved in men, in patients who did not have a family history of psychiatric illness, and
in patients who were treated with atypical antipsychotics. The level of social integration was
better in patients who were treated with atypical antipsychotics but this effect depended on the
type of schizophrenia.


schizophrenia, quality of life, SWN-S, WHOQoL–BREF, gender, treatment type, family
history

✓

The level of social integration, self-control and physical function is better in subjects who
are treated with atypical neuroleptics.
Self-control, physical function and the capacity of emotional control is equally affected
in both women and men with, while mental functioning would be better preserved in men.
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Introduction
Quality of life is a construct represented by an
individual’s subjective perception of his/her self in
relation to his place and existence/ adaptation in life,
judged according to a cultural, social, and personal
system of values (generally governed by objectives,
expectations, standards, etc.) (1).
Schizophrenia is a disabling chronic psychiatric
illness which affects most (if not all) major fields of
mental functioning. The disease is equally prevalent in
both men and women. However, the onset and course of
illness differs between the two genders. Women show
an incidence peak for schizophrenia between 21 and 25
years, compared to 25-32 for men, and women also
show a second incidence peak in the fourth decade of
life (2, 3).
Several studies have shown that the quality of life
of female patients suffering from schizophrenia takes a
smaller toll compared to male patients, probably due to
a reduced number of hospital admissions, lower doses of
medication for women, and generally faster remissions
(4, 5). Considering long-term prognosis, however, the
research literature indicates a slight trend toward poorer
outcomes in female patients (6). Regarding other
differences, men tend to be more predisposed to
substance abuse and anti-social behaviors (4, 7),
whereas women are more prone to symptoms from the
affective spectrum (8).
Quality of life has become a major area of interest
due to the disabling aspect of schizophrenia. In addition,
it is well known that schizophrenia and schizophreniarelated disorders present an increased incidence among
the first-degree relatives of patients who suffer from this
illness (9).
The neuroleptic medication used to treat
schizophrenia consists of two broad categories: typical
and atypical antipsychotics. Although the available
drugs have a wide array of pharmacological properties,
generally all these drugs have the capacity to antagonize
postsynaptic dopamine receptors in the brain. Dopamine
and the quality of life are mutually linked through the
brain’s reward system. Further assessment of the quality
of life needs to take in account the type of drug used,
even though all relevant drugs share a common final
endpoint (9).

Materials and Methods
One hundred and forty-three patients were included
in this study, being admitted in “Prof. Dr. Alexandru
Obregia” Clinical Hospital of Psychiatry during a 3-year
period (2009-2012). The diagnosis of schizophrenia was

established according to DSM- IV-TR (10) and ICD 10
(11) criteria. Patient ages ranged from 18 to 65 years,
and 58.7% were female.
More than three quarters of the sample was
diagnosed with paranoid schizophrenia (75,5%), 14,7%
with undifferentiated schizophrenia, 5,6 % with residual
schizophrenia,
and
4,2%
with
hebephrenic
schizophrenia. Because patients diagnosed with simple
schizophrenia made up only 0,9 of the sample (1 case),
this segment was not included in the analysis.
Most subjects included in the lot (60,8%) did not
have a family history of psychiatric illness. 86,3% of the
patients diagnosed with schizophrenia and included in
the lot followed a treatment plan based on an atypical
neuroleptic, while only 13,7% of them received
treatment with a typical neuroleptic.
All patients were undergoing antipsychotic
treatment for at least 4 weeks before admission. The
study was approved by the Ethics Committee of the
“Prof. Dr. Alexandru Obregia” Clinical Hospital of
Psychiatry, Romania. Patients also received an informed
consent form and given time to consider participation;
all concerns were addressed before obtaining their
signed approval.
Clinical variables and psychological parameters
were evaluated using the following standardized scales:
• Subjective
Well-being
under
Neuroleptic
Treatment Scale (SWN) (12-14), a self-assessment scale
with the initial form of 38 items and a short variant of
20 items (10 negative and 10 positive scored items),
each being scored on a Likert 6-step scale. The purpose
of the scale is to show the subjective experience of the
patient during neuroleptic treatment, having 5 distinct
topics: physical functioning, mental functioning, selfcontrol, emotional regulation, and social integration. A
high value indicates better functioning of the patient on
the respective domain. The scale has an overall
evaluation of both the efficiency and the quality of the
medical treatment in schizophrenia, but it also includes
the subjective well-being of the respondents, and further
offers the possibility of evaluating the subjective
perception of the patient, no matter the psychopathology
(15, 16).
• World Health Organization Quality of Life (WHOQoL – BREF) (17-19); in our analysis, we used scores
related to 4 domains of quality of life (physical,
psychological, social, and living environment), while 2
other items were evaluated separately. The patients’
answers were quantified using a 5-step Likert scale.
High values correspond to a high level of satisfaction
regarding quality of life (20-22).
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Statistical processing was performed using the IBM
SPSS Statistics 20 program (23, 24). A specific
objective of our study was to investigate several tests/
results between distinct lots, created according to
gender, type of schizophrenia, type of antipsychotic
used, and family history of psychiatric illness. For this
purpose, inferential statistics were used, namely
parametric difference tests (“t” tests and ANOVA) or
non-parametric tests (Chi square); we opted to use
parametric tests when possible as they are more
powerful statistically.

Results

Table 1. SWN-S subscale values according to
gender
Gender

N

Mean

Woman
Mental
functioning Man

84

10,692

3,5901

,3905

59

11,978

3,9007

,5100

Woman

84

11,123

3,8961

,4238

Man

59

12,311

3,0507

,3989

Physical
functioning

Woman

84

11,831

4,5181

,4915

Man

59

12,667

4,1994

,5490

Emotional
regulation

Woman

84

12,477

5,0069

,5447

Man

59

11,889

4,1081

,5371

Social
integration

Woman

84

10,569

4,3901

,4776

Man

59

11,222

3,4016

,4447

Self-control

Std.
Deviation

Std. Error
Mean

1. Differential aspects of SWN-S in schizophrenia
The data show that mental functioning is less
patients.
affected in men. Self-control, physical functioning,
emotional control, and social integration are equally
1.1 SWN-S and gender differences
The means and standard deviations for the two affected in women and men suffering from
genders on each test dimension are represented in Table 1. schizophrenia (Table 2).
Table 2. SWN-S subscale „t” values according to gender
Levene's Test for
EVa
F

EVA

1,615

,206

EVA

3,459

,065

Mental
functioning EVnA
Selfcontrol

Sig.

EVnA

EVA
Physical
functioning EVnA
Emotional
regulation

EVA

Social
integration

EVA

,373

,543

t-test for Equality of Means
t

Sig. (2tailed)

Mean
Difference

Std. Error
Difference

95% CI of the Difference
Lower

Upper

-2,032

141

,044

-1,2855

,6327

-2,5362

-,0347

-2,001

117,006

,048

-1,2855

,6424

-2,5576

-,0133

-1,954

141

,053

-1,1880

,6081

-2,3903

,0142

-2,041

138,801

,043

-1,1880

,5820

-2,3388

-,0373

-1,119

141

,265

-,8359

,7468

-2,3123

,6405

-1,134

129,372

,259

-,8359

,7369

-2,2938

,6220

,5880

,7928

-,9793

2,1554

2,507

,116

,742

141

,460

,769

136,886

,443

,5880

,7650

-,9246

2,1007

7,954

,005

-,956

141

,341

-,6530

,6831

-2,0035

,6975

-1,001

139,152

,319

-,6530

,6526

-1,9433

,6373

EVnA
EVnA

df

1.2 SWN-S and type of schizophrenia
The impact of the type of schizophrenia was tested
on the quality of life using the 5 dimensions of the SWNS questionnaire. The data showed a significant
difference between the types of schizophrenia on 3 of
the 5 dimensions: mental functioning F (3,138)=2.81,
p=0.042, emotional regulation F(3,138)=2.78, p=0.043
and social integration F(3,138)=5.58, p=0.001.
Post-hoc Bonferroni tests highlighted the fact that
this difference was significant only for the social
integration dimension: between the residual type of
schizophrenia and the paranoid type of schizophrenia,
hebephrenic type and undifferentiated type, in the case
of the residual type, social integration level being

significantly higher. This difference is further illustrated
in Figure 1:

Figure 1. Differences regarding social integration
based on the type of schizophrenia
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1.3 SWN-S and family history of psychiatric illness

2.2 Type of Schizophrenia

Variation in the quality of life was also tested across
samples having different family histories of psychiatric
illness. Mental functioning, self-control, and physical
functioning were better preserved in patients who did
not have a family history of psychiatric illness versus
those who did (t(141)=2.43, p=.016), (t(141)=3.06,
p=.003), (t(141)=2.94, p=.004) respectively. As for
emotional regulation and the capacity of social
integration, no significant differences were found:
t(141) =1.6, p>.05 and t(141)=.94, p>.05 respectively.

Patients
suffering
from
undifferentiated
schizophrenia registered the highest mean scores for all
4 dimensions of the WHOQoL-BREF scale. The lowest
mean scores were registered by patients diagnosed with
hebephrenic schizophrenia on the Psychological and
Environment dimensions, and by patients diagnosed
with residual schizophrenia on the Physical health and
Social relationships dimensions. However, ANOVA did
not indicate statistically significant differences
regarding schizophrenia type on these four dimensions:
Physical health (f=0,949, df=3, p>0,05), Psychological
(f=0,223, df=3, p>0,05), Social relationships (f=1,379,
1.4 SWN-S and antipsychotic type
df=3, p>0,05) and Environment (f=1,117, df=3,
Quality of life variation was tested across types of
p>0,05), based on the type of schizophrenia (Figure 3).
antipsychotic currently used. Analysis of variance
showed significant differences on all 5 dimensions of
SWN-S. Mental functioning was better maintained in
the patients under treatment with atypical
antipsychotics, versus the patients treated with typical
antipsychotics (t (141)=4.01,p<.001).
Self-control
(t(141)=3.77,p=.001),
physical
function (t (141)=3.90, p=.001), emotional regulation (t
(141) =3.12, p=.002), and social integration
(t(141)=2.79, p=.006) were better preserved in patients
who underwent treatment with atypical antipsychotics
versus those treated with typical antipsychotics.
2. Differential aspects of WHO-QoL-BREF
2.1 Gender
By analyzing the mean scores based on gender, it
can be seen that male patients register higher scores for
all WHO-Q0L-BREF dimensions compared to female
patients (Fig. 2).

2.3 Family history of psychiatric illness
Analyzing the mean scores of the WHO-QoL –
BREF scale, our study showed lower mean scores for
Physical health, Psychological, and Environment
dimensions, for patients who had a family history of
psychiatric illness (Figure 4).

Figure 2. Mean WHO-QoL scores based on
gender (blue = female; red = male)
Significant gender differences were obtained only
for the Physical Health Dimension (T= -2,997,
df=141,p<0,01) and Psychological Dimension (t=Figure 4. Mean WHOQoL scores based on family
2,559, df=141, p<0,01).
history of psychiatric illness
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Table 3. T test for separate lots– WHOQoL-BREF * Family history of psychiatric illness
F
Sig.
t
df
Sig.
Mean
Std. Error
95% CI of the
(2-tailed) Difference Difference
Difference
Lower
Upper
EV
6.913 .010 2.103
141
.037
5.3360
2.5370
.3205 10.3515
Mean
EVnA
1.972 92.898
.052
5.3360
2.7061
-.0378 10.7098
Regarding the Social relationships dimension,
although patients having a family history of psychiatric
illness registered higher mean scores, the differences
were not statistically significant (Table 3).
2.4 Antipsychotic type:
Regarding type of medication, higher mean scores
were registered by the patients who followed a treatment
plan with an atypical antipsychotic. However, a
significant difference was observed only for the Social
relationship dimension (Figure 5).

Figure 5. Mean WHOQoL scores based on type of
antipsychotics used

Discussions
Taking into consideration the chronic and
debilitating characteristics of schizophrenia, a series of
factors that influence quality of life have been studied
by specialists in the field. Clinical characteristics,
treatment related issues, and socio-demographical
factors for a long time represented the main focus of
researchers when discussing influences on quality of
life. With the introduction of atypical antipsychotics
which are able to control the positive symptoms (while
presenting a low profile of major side effects), the focus
on quality of life shifted from an objective perspective
to a subjective one, represented by “the person’s sense
of well-being and satisfaction with life” (25). The aim
of the current study was to assess the impact of gender,
type of schizophrenia, family history of psychiatric
illness, and type of treatment administered on the
perceived level of quality of life of patients suffering
from schizophrenia.
The association between gender and perceived level
of quality of life had not been reported in many studies.
In those studies, women generally had a lower degree of

disability and a better quality of life. To explain these
differences, the following hypotheses had been
suggested: the later onset of the illness in female patients
on one hand, and the more frequent occurrence of
negative symptoms associated with behavioral problems
in men (that may contribute to a higher level of
deterioration of functioning in male patients), on the
other hand (26-28). An alternative explanation for the
differences of quality of life between men and women
may be related to treatment response; female patients
respond faster and also at lower doses, a result that could
lead to better treatment compliance (29, 30).
Overall, our study revealed better outcomes in male
patients on all of the domains of the WHO-QoL – BREF
score, while the SWN-S questionnaire showed a
statistically significant difference only in the mental
functioning domain. Our results contrast with those
reported by Shtasel et al (on patients without
medication) who concluded that women had a better
quality of life than men, specifically in the social and
relationship domains (31). Our findings using the WHOQoL – BREF score were similar to the results obtained
of Yu-Tao Xiang and colleagues who showed that
female patients suffering from schizophrenia had a
lower quality of life than men who had the same illness
(32).
Many studies have shown the benefits of atypical
antipsychotics regarding quality of life (33). Ritchie et
al. (2003) revealed improvement in quality of life scores
when switching from typical to atypical antipsychotics,
specifically regarding olanzapine and risperidone
administration (34). Voruganti et al. (2002) concluded
that quality of life was improved for all patients who
were switched to atypical antipsychotics, with no
significant differences between the chosen antipsychotic
(35). Our study reported higher quality of life regarding
all domains analyzed by the two scales. Crossley et al.
(2010) correlated better quality of life with a lower
prevalence of extrapyramidal side effects when using
atypical antipsychotics (36), providing a possible
explanation for the results obtained in our study.
Our results were consistent with those of Kilian and
Angermeyer (2005) regarding mental functioning,
which was better preserved in patients treated with
atypical antipsychotics, but in contradiction with their
other findings, as they found no significant differences
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between patients treated with atypical antipsychotics
and those treated with conventional ones concerning
other domains of quality of life (37).
Psychiatric symptoms were frequently perceived to
have a negative impact on quality of life (38), but it was
difficult to assess which had the largest influence;
studies consistently have shown that negative symptoms
have a greater effect on quality of life than positive
symptoms (39-41).
Our results are similar to those of Sigaudo et al
(2014) which refer to the disorganization symptoms as a
main factor leading to poor quality of life, especially in
role-functioning and intrapsychic functioning domains
(in our sample the hebephrenic type of schizophrenia
registered the lowest scores in the Psychological and
Environment dimensions) (42, 43).
Study limitations: the number of patients included
in the study was relatively low and patients were not
equally distributed by gender (women being more than
men), and these factors might have contributed to
inconsistency of our results with other data from
literature as well as diminished ability to generate to the
population (44). Our sample consisted of patients under
stable medication, so we did not assess the dynamic of
switching from a typical antipsychotic to an atypical
one. Our study was also performed without a control
group.
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